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ABSTRACT
The mammalian polycomb group proteins play
an important role in cell cycle control and tumorige-
nesis. Nervous system polycomb 1 (NSPc1) is a
newly identified transcription repressor, highly
homologous with PcG protein Bmi-1. In this article,
we showed that NSPc1 could promote tumor cell
cycle progression and cell proliferation. Semi-
quantitative RT–PCR showed that NSPc1 did not
affect the expression levels of most Cyclin-depentent
kinases (CDK) inhibitors except for p21Waf1/Cip1.
Repression activity assays, chromatin immunopre-
cipitation (ChIP) and DNA pulldown assays all
verified that NSPc1 represses the expression of
p21Waf1/Cip1 by binding to the ( 1357 to  1083)
region of the p21Waf1/Cip1 promoter in vivo, and the
repression effect is dependent on the retinoid acid
response element (RARE element) within the above
region of the p21Waf1/Cip1 promoter. Further anal-
ysis showed that NSPc1 could compete the RARE
element site with RA receptors both in vitro and
in vivo. Taken together, our results support the
hypothesis that NSPc1 has a positive role in tumor
cell growth by down-regulating p21Waf1/Cip1 via
the RARE element, which directly connects tran-
scriptional repression of PcGs to CDKIs and RA
signaling pathways.
INTRODUCTION
Polycomb group (PcG) Proteins are epigenetical chromatin
modiﬁers that can transcriptionally silence their targets
through cell division during development and therefore
provide a cellular memory mechanism (1,2). Since PcG
proteins were ﬁrst discovered in Drosophila as the regulator
of homeotic (Hox) genes expression, many mammalian
homologues of PcG proteins have been identiﬁed so far.
The mammalian PcG proteins are classiﬁed into two major
Polycomb Repressive Complexes (PRCs). Among them,
Mel-18, Bmi-1, MBLR and NSPc1 are classiﬁed into the
Polycomb Repressive Complex 1 (PRC1) based on their
structural similarities with the Posterior sex comb (Psc)o f
Drosophila (3–7). Now accumulated evidence indicates that
these mammalian homologues of Psc protein may be impli-
cated in cell cycle control, cell proliferation and tumorigene-
sis (8). For instance, Bmi-1 is a proto-oncogene to induce
mouse lymphoma in association with c-myc (9), and Bmi-1
can also promote cell proliferation and stem cells self-
renewal by repressing the p16INK4a/p19ARF locus (10).
On the contrary, Mel-18 is a transcriptional negative regu-
lator with tumor suppressor activity (11), and could also
inhibit the proliferation in differentiated B lymphocytes
through a c-myc/cdc25 cascade (12).
The human NSPc1 gene encodes a protein that shares high
homology with Mel-18 and Bmi-1 (4). Moreover, NSPc1
protein is mainly localized in the nucleus and has a transcrip-
tion repression activity (13). Recently, NSPc1 is identiﬁed as
one of the genes highly expressed in HCT-116 deprived
tumors grown in C.B-17 SCID mice (14), one of the most
differentially expressed genes in HeLa cells after camp-
tothecin treatment (15) and one of the 32 marker genes in
kidney cancers (16). These evidences infer that NSPc1 may
play a role in the pathogenesis of tumors. However, until
now little is known about whether NSPc1 has a role in
tumor cell cycle control and tumorigenesis.
Cell cycle progression in eukaryotic cells is ﬁnely
regulated by the sequential activation of cyclin-dependent
kinases (CDKs), which are activated after interaction with
their corresponding cyclins (17). The activity of these
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doi:10.1093/nar/gkl834CDKs is restrained by two groups of CDK inhibitors
(CDKIs): the INK4 family, which includes CDKN2A/p16
ARF, CDKN2B/p15 INK4B, CDKN2C/p18 INK4C,
CDKN2D/p19 INK4D; and the Cip/Kip family, consisting
of CDKN1A/p21 CIP1, CDKN1B/p27 KIP1, CDKN1C/p57
KIP2 (18). The kinase inhibitor p21 Waf1/Cip1 (hereafter
p21) retards S phase progression by inhibition of cyclin-
dependent kinases (19) and functions as a G2 checkpoint
by binding to cyclin B1–cdc2 complexes, which are integral
in the G2/M transition (20,21). Deregulation in the expression
of p21 would be expected to result in abnormal cell prolifera-
tion and to predispose the cells to transformation (22,23).
PcGs have been found to repress some negative cell cycle
regulators to promote cell cycle transition and cell prolifera-
tion (8,24,25). For example, PcG proteins Bmi-1 and Cbx-7
have been identiﬁed to regulate cell proliferation by repress-
ing the p16ARF/p19INK4a locus in different tissues and
cell lines (9,26). In the present study, we explored the
role of NSPc1 in tumor cell growth regulation and demon-
strated that p21 is the direct target gene regulated by
NSPc1. The underlying molecular mechanism has also been
investigated.
MATERIALS AND METHODS
Cell culture and transfection
HeLa or COS-7 cells were maintained in DMEM, SH-SY5Y
in RMPI 1640 with 10% heat-inactivated FBS, 50 U/ml
penicillin, and 50 mg/ml streptomycin under a humidiﬁed
atmosphere of 5% CO2 and 95% air at 37 C. Lipofectamine
2000 (Invitrogen, USA) was used to transfect cells according
to the manufacturer’s instructions.
Flow cytometric analysis
Flow cytometric analysis was carried out at the Flow
Cytometry facility of PUMC. Brieﬂy, cells grown on
100 mm tissue culture dishes to 70% conﬂuency were trypsi-
nized, pelleted and washed with pre-chilled phosphate-
buffered saline (PBS). Cells were ﬁxed at  20 C overnight
with 70% ethanol, washed with PBS, and resuspended in
0.1% Triton X-100 containing RNase A (200 mg/ml,
Sigma) and propidium iodide (200 mg/ml, Sigma). Cells
were then incubated at room temperature for 30 min before
detection. Data were collected using a Becton–Dickinson
FACScan apparatus with doublet discrimination and analyzed
using the CELL Quest (Becton–Dickinson) and ModFit
LT 3.0.
Establishment of NSPc1 stably integrated cell pools and
NSPc1 knocked down cell pools
To establish NSPc1 stably integrated HeLa cell pools,
the coding sequence of NSPc1 was inserted into
pcDNA3.1-V5 (Invitrogen, USA) for transfection into HeLa
cells. A control set of cells was transfected with empty vec-
tor. After 24h of transfection, the growth medium was
replaced with fresh DMEM containing all of the supplements
listed above, as well as 600 mg/ml G418 (Gibco, USA) in
order to select for geneticin-resistant cells. After 2–3 weeks
of selection, pools of G418-resistant cells, denoted as
‘NSPc1 + V5’ and ‘V5’, respectively, were identiﬁed with
semi-quantitative RT–PCR and western blot. To establish
NSPc1 knocked down cell pools, the IMG800-based plasmids
(GeneSuppressor system, Imgenex, USA), which contains the
human U6 promoter, were constructed as described by the
manufacturer http://www.imgenex.com. Brieﬂy, several
21-nucleotide sequences within the coding region of NSPc1
were selected as candidates and the PCR ampliﬁed fragments
were inserted into the IMG800 vector. Final constructs
including the region of nt 94–114 and nt 515–536 were
used and named ‘RNAi1’ and ‘RNAi2’, respectively. The
two RNAi constructs were then transfected into HeLa cells
along with IMG800 empty vector as a control. After 24 h
of transfection, the cells were switched to grow in the pres-
ence of G418 (600 mg/ml). After 2–3 weeks of selection,
pools of G418-resistant cells, denoted as NSPc1-RNAi1, 2
and IMG800 (control), were also identiﬁed with the same
methods. These above mentioned cell pools were then
replated, expanded and maintained in complete media
containing 300 mg/ml G418 as stable integrated cell pools.
For experiments described below, log phase cells between
4th and 10th passages were utilized.
Semi-quantitative RT–PCR analysis
Total RNA was isolated from the stable cell pools using
reagent Trizol (Invitrogen, USA) according to the manufac-
turer’s instructions. Reverse transcription was performed
using a ﬁrst-strand cDNA kit (Life Technologies, USA)
following the protocol recommended by the manufacturer.
RT–PCR exponential phase was determined on 25–35 cycles
to allow semi-quantitative comparisons among cDNAs devel-
oped from identical reactions. Each PCR regime involved a
5 min initial denaturation step at 94 C, followed by amplica-
tion cycles (e.g. 25 cycles for GAPDH and 32 cycles for
NSPc1 and p21) of 94 C for 30 s, 57 C for 30 s, and ﬁnal
extension at 72 C for 30 s. The primers are NSPc1-up: 50-ga
gacacagccactgctcaa-30, NSPc1-down: 50-tgcacatgctgagggttt
ag-30; GAPDH-up: 50-accacagtccatgccatcac-30, GAPDH-
down: 50-tccaccaccctgttgctgta-30; and CDKN1a (p21Cip1/
Waf1)-up: 50-atgtggacctgtcactgtcttgta-30, CDKN1a (p21Cip1/
Waf1)-down: 50-agggtatgtacatgaggaggtggt-30; CDKN1b (p27
kip1)-up: 50-catttggtggacccaaagac-30, CDKN1b (p27kip1)-
down: 50-cctcccttccccaaagttta-30; CDKN1c (p57Kip2)-up:
50-agatcagcgcctgagaagtc-30, CDKN1c (p57Kip2)-down: 50-gg
gaccagtgtaccttctcg-30; CDKN2a (p16Arf/Ink4a)-up: 50-gcacca
gaggcagtaaccat-30, CDKN2a (p16Arf/Ink4a)-down: 50-cgtgag
tgctcactccagaa-30; CDKN2b (p15Ink4b)-up: 50tagtggagaaggtg
cgacag-30, CDKN2b (p15Ink4b)-down: 50gggtgggaaattgggtaa
ga-30; CDKN2c (p18Ink4c)-up: 50-acgtcaatgcacaaaatgga-30,
CDKN2c (p18Ink4c)-down: 50-gcctgcatcaggctaacaac-30;C D
KN2d (p19Ink4d)-up: 50-ctgcaggtcatgatgtttgg-30, CDKN2d
(p19Ink4d)-down: 50-aagccacaaactgtgctcct-30; Bmi-1-up: 50-
acgcaaaaccgatcaaagaa-30, Bmi-1-down: 50-gctggtaagcaaggct-
caac-30. Equal volumes of PCR mixtures were resolved on
1.5% agarose gels and visualized by ethidium bromide staining.
Cell extracts and western blotting
To detect the endogenous NSPc1 protein level in the stable
cell pools, whole cell extracts were prepared and assayed
using western blot as described before (13). Additionally,
mouse monoclonal anti-FLAG (1:5000, Sigma, USA),
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USA) and anti-b-actin (1:5000, Sigma, USA) antibodies
were used for detection of their corresponding proteins. The
horseradish peroxidase (HRP)-conjugated anti-mouse IgG
(1:4000, Santa Cruz Biotechnology, USA) was used as the
secondary antibody and signals were visualized using the
enhanced chemiluminescence system (ECL, Amersham
Biosciences, USA).
Cell proliferation by MTT assay
Cell proliferation was quantiﬁed using MTT assay (3-[4,5-
dimethylthiazol-2-yl]-2,5 diphenyl tetrazolim bromide
assay). The HeLa stable cell pools seeded on 96-well
microplates at 6000 cells/well were incubated in DMEM
medium containing 300 mg/ml of G418 for 1–7 day prior to
be assayed. The medium was changed once with fresh culture
medium on the third day. MTT assay was performed after 1,
3 or 5, 7 days as described before (27). Brieﬂy, cells were
incubated with 0.5 mg/ml of MTT (Sigma) for 4 h in a
CO2 incubator at 37 C. After the removal of the solution,
the purple precipitates were dissolved in DMSO for 20 min
at room temperature and the resultant solution was transferred
to new 96-well plates. The absorbance was measured at
570 nm using a Labsystems Multiscan RC enzyme-linked
immunosorbent assay (ELISA) reader. Each experiment was
performed in triplicate, and the means were determined for
each time point.
Colony formation assay
For colony formation assays, cells derived from NSPc1-V5
and NSPc1-RNAi1 stable cell pools were plated under sparse
conditions (1000 cells per well of 6-well plate in triplicate)
with 4% methyl cellulose semi-solid DMEM medium and
fed with fresh DMEM growth medium containing
300 mg/ml of G418 every 2–3 days. After 2 weeks, the plates
were stained with crystal violet in 20% ethanol and pho-
tographed. The total number and the number of colonies
greater than 2 mm in diameter were counted and the means
and SDs were determined for each pool. The clonogenic
assay was performed three times, which generated almost
identical results.
Repression activity assays
Full-length of NSPc1, Bmi-1, c-Myc and RXRa was
subcloned into the pcDNA6-FLAG (Invitrogen, USA) vector.
The human p21Waf1/Cip1 promoter constructs (2.3 kb,
1.8 kb, mut-RARE and mut-E-box fragments of the p21 pro-
moter construct ligated to pGL3-basic vector) were the gen-
erous gifts from Dr Gallego, C., as described previously
(28). Synthetic Renilla Luciferase Report Vector (pRL-TK)
was purchased from Promega. Repression activity assays
were performed as described before (13). In short, exponen-
tially growing COS-7 or HeLa cells were seeded onto 24-well
plates at a density of 2 · 10
4 cells/well, 1 day prior to trans-
fection. Cells were transfected with pcDNA6-FLAG-NSPc1,
pcDNA6-FLAG-Bmi-1, pcDNA6-FLAG-RXRa and/or
pcDNA6-FLAG-c-Myc, together with reporter plasmid
pGL3-p21 promoter series (200 ng/well) and pRL-TK
(100 ng/well) as an internal control. Total amounts of trans-
fected DNA were equalized by the addition of empty vector
(pcDNA6-FLAG). Each transfection reaction was performed
in triplicate. After 24 h post transfection, the medium was
aspirated, and cells were harvested and assayed for luciferase
activity by using the Dual-luciferase reporter assay system
(Promega, USA). Results were obtained from three different
transfection experiments after normalization for the internal
control of TK activity. Experimental variations are indicated
as means ± SDs.
Chromatin immunoprecipitation (ChIP) assay
Approximately 2 · 10
8 (common PCR) or 2 · 10
7 (for
Absolute Quantitative PCR) subconﬂuent HeLa cells grown
in DMEM medium were collected, and native protein–DNA
complexes were cross-linked by treatment with 1% formalde-
hyde for 15 min. The ChIP assay was generally carried out as
reported earlier (29). Brieﬂy, equal aliquots of isolated chro-
matin were subjected to immunoprecipitation with rabbit
anti-NSPc1 antibody (13), RXRa antibody (Santa Cruz),
pre-immunized sera or mouse IgG. The DNA fragments
associated with speciﬁc immunoprecipitates or with negative
control preimmune serum were isolated and used as templates
for subsequent PCR reactions to amplify the p21 promoter
sequences. The primers for the upstream region ( 2264 to
 1971) were: 50 primer, 50-ttgagctctggcatagaaga-30;3 0 primer,
primer, 50-tacccagacacactctaagg-30. The primers for the RA
response element region ( 1357 to  1063) were: 50 primer,
50-agactctgagcagcctgag-30;3 0 primer, 50-aaccctcatttgcagatggt-30.
The primers for the downstream core promoter region
( 194 to +81) were: 50 primer, 50-accggctggcctgctggaact-30;
30 primer, 50-tctgccgccgctctctcacct-30. The primers for the
GAPDH 2nd intron: 50 primer, 50-aatgaatgggcagccgttag-30;
30 primer, 50-agctagcctcgctccacctgac-30.
Absolute quantitative PCR
Absolute quantitative PCR was performed using the standard
curve method and SYBR Green Chemistry on Applied Bio-
systems 7500 SDS instruments. Brieﬂy, generate a stand-
ard curve for the target amplicon by plotting the Ct value
versus amount of HeLa genomic DNA template (100, 50,
12.5, 3.12, 0.78 and 0.39 ng by serial dilution). The amount
of target DNA in the given ChIP sample from normal, NSPc1
over-expressed or knocked-down HeLa cell was quantiﬁed by
using the above mentioned standard curve. Real-time PCR
ampliﬁcation was performed in 20 ml reaction mixture
containing 1 ml of ChIP DNA sample, 10 ml of QuantiTect
SYBR Green PCR Master Mix (Applied Biosystems) and
5 pmol of speciﬁc primers that are listed as the follows:
upstream, 50-gcaaatgtttcaggcacaga-30; downstream, 50- tctacc-
tcacacccctgccc-30. The data were used to calculate the ratio of
total amount of precipitated DNA in different samples to the
initial amount of input DNA used for immunoprecipitation.
Results were expressed as means ± SDs. An analysis of vari-
ance with ANOVA was used to examine differences between
groups.
DNA pulldown assays
DNA pulldown assays were carried out following a previous
description (30). COS-7 Cells were lysed by sonication
in HKMG buffer (10 mM HEPES, pH 7.9, 100 mM
KCl, 5 mM MgCl2, 10% glycerol, 1 mM DTT and 0.5%
6160 Nucleic Acids Research, 2006, Vol. 34, No. 21NP-40) containing protease and phosphate inhibitors. Cellular
debris was removed by centrifugation. 1 mg of cell exacts
were precleared with 40 ml of streptavidin-agarose beads
(Amersham Bioscience) for 1 h at 4 C, then incubated
with 2 mg of biotinylated double-stranded oligonucleotides
and 40 mg of poly(dI–dC)·(dI–dC) for 16 h at 4 C. DNA-
bound proteins were collected with 60 ml of streptavidin–
sepharose beads for 1h at 4 C, washed twice with
HKMG buffer, separated on a SDS–PAGE, and identiﬁed
by western blot. The biotinylated double-stranded oligonu-
cleotides were ampliﬁed using the following 50-terminal
biotinylated primers with the same sequences in ChIP detec-
tion: the primers for the RA response element region ( 1357
to  1063) were: 50 primer, 50-biotin-agactctgagcagcctgag-30;
30 primer, 50-aaccctcatttgcagatggt-30; the primers for the
downstream core promoter region ( 194 to +81) were: 50
primer, 50-biotin-accggctggcctgctggaact-30;3 0 primer, 50-tctgc
cgccgctctctcacct-30. The mutant-RARE DNA amplicons
were ampliﬁed using the pGL3-mutantRARE-p21-promoter
constructs as the template.
RESULTS
Transiently over-expressed NSPc1 affects cell cycle
distributions of HeLa and SH-SY5Y cells
Many members of the polycomb complexes have been
implicated in cell cycle control. To test whether NSPc1 has
a similar role in tumor cell growth as Mel-18 and Bmi-1,
we transiently over-expressed NSPc1 in HeLa (PcG members
enriched cell line) and SH-SY5Y (endogenous NSPc1
expressed cell line) cells. Cell cycle distributions were
determined by analysis of their total DNA content. The
cells with 2n DNA were classiﬁed as G0/G1 populations,
those with 4n DNA were classiﬁed as G2/M populations,
and those with DNA content 2n–4n were assigned to be in
the S phase of the cell cycle. Flow cytometric analysis
showed an S phase increase and a G2/M phase decrease in
both cell lines after transient NSPc1 over-expression
(Figures 1 a–f).
NSPc1 promotes tumor cell cycle progression and
enhances cell proliferation
NSPc1 stably over-expressed and knocked-down HeLa cell
pools were established to verify its effect on cell proliferation.
The IMG800 plasmid, which contains the human U6 promoter
and a neomycin resistance gene, was used to establish the
NSPc1 stably knockdown HeLa cell pool. Several constructs
that direct synthesis of NSPc1 siRNAs in vivo were designed
as mentioned in materials and methods. The expression level
of NSPc1 in the above HeLa cell pools were analyzed both
at the mRNA and protein level (Figure 2a).
Flow cytometric analysis demonstrated that the cell cycle
distributions of the above mentioned stable HeLa cell pools
showed the similar pattern as in Figure 1 (Figures 2b
and c). Stable over-expression of NSPc1 in HeLa cells caused
S phase increase and G2 phase decrease or G2/M transition
(Figure 2b). While RNAi NSPc1 in HeLa cells led to the
reverse effects, and it seemed that the ‘RNAi1’ construct
was more effective (Figure 2c). Furthermore, the results
from MTT assays demonstrated that the expression level of
NSPc1 could also inﬂuence the proliferation rate of HeLa
cells (Figure 2d and e). Since HeLa cell is a tumor cell line
with colony formation ability in semi-solid culture medium,
we addressed the question whether NSPc1 interferes with
the colony formation ability of this tumor cell line. Consider-
ing that the siRNA synthesized from the ‘RNAi1’ constructs
seemed to be more effective in HeLa cells (Figure 2a), we
only chose the ‘RNAi1’ and ‘NSPc1’ stable cell pools to
compare cell colony formation activity. As shown in Figure
2f and g, there was about an average of 25% decrease in
colony number and a decrease in average colony size in the
‘RNAi1’ pool compared to the ‘NSPc1’ pool. All these
results proved that NSPc1 not only promotes HeLa cell
cycle progression, but enhances cell proliferation as well.
Figure 1. Flow cytometric analysis of HeLa and SH-SY5Y cells transiently transfected with pcDNA3.1-v5+NSPc1 or control vector. A representative
experiment out of at least three performed is shown both in cell phase distribution and bar diagrams. (a–c) HeLa cell, (d–f) SH-SY5Y cell.
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inhibitor p21
PcGs have been found to repress some negative cell cycle
regulators to promote cell cycle transition and cell proliferation
(8,24,25). For example, the p16ARF/p19INK4a locus has
been veriﬁed as the key target of PcG proteins Bmi-1 and
Cbx-7, and the two CDKIs from this locus are partially
responsible for the effect of Bmi-1 and Cbx-7 on cell growth
regulation (9,26). Therefore, we speculated that NSPc1, as a
typical PcG member, could also promote cell growth through
repressing some negative cell cycle regulators, specially the
CDK inhibitor family members. To ﬁnd out the possible
CDK inhibitors involved, the expression levels of the CDK
inhibitors were assessed in our stable HeLa cell pools with
semi-quantitative RT–PCR. GAPDH and Bmi-1 were
ampliﬁed as controls. As shown in Figure 3a, only the
expression of p21 was repressed. Western blot results showed
the similar expression pattern of p21 (Figure 3b).
NSPc1 represses p21 promoter activity in a dose
dependent manner but independent of p53
To elucidate the molecular mechanisms of the repression of
p21 by NSPc1, we examined the effect of over-expressed
NSPc1 on the transcription activity of the p21 promoter by
using dual luciferase report assay. Considering that the proxi-
mal 2.3 kb region of the p21 promoter has been well studied
(31), we mainly focused on this 2.3 kb region in the following
repression activity assays. The plasmid pGL3Basic-2.3kb p21
promoter and its derivative plasmids, which were described
by Liu et al. (28), were kindly represented by Dr Gallego
C. and used in the current work. Meanwhile, c-Myc was
included as a positive control since it represses the expression
of the luciferase reporter gene driven by a p21 promoter (32).
As shown in Figure 4a, over-expression of NSPc1 in COS-7
cells led to a  45% decrease of relative luciferase activity
compared with control, although over-expression of c-Myc
led to a stronger repression ( 60% decrease) on the p21
Figure 2. Effects of NSPc1 on HeLa cell cycle progression, cell proliferation and cell colony formation. (a) Establishment of the NSPc1 stably over-expressed
and NSPc1 knocked-down HeLa cell pools. Up: changes in mRNA level of HeLa stably transfected cells pool confirmed by semi-quantitative RT–PCR. PCR
products generated by primer sets for NSPc1 were normalized by glyceraldehyde-3-phosphate dehydrogenase (GAPDH); Down: changes in protein expression
confirmed by Western blots (normalized by b-actin protein level). (b and c) Flow cytometric analysis of HeLa stable cell pools. (d and e) MTT assay of HeLa
stable cell pools. (f and g) Colony formation assay. Culture dishes fixed and stained with 0.1% crystal violet at the end of the experiment. The numbers of total
colonies and colonies greater than 2 mm in diameter were counted and the means and SDs of three independent experiments were shown. Abbreviations: V5,
pcDNA3.1-V5 cell pool; NSPc1, pcDNA3.1-V5+NSPc1 cell pool; IMG800, IMG800 cell pool; RNAi1, NSPc1-RNAi1 cell pool; RNAi2, NSPc1-RNAi2 cell
pool. Note: a representative experiment out of three performed is shown in (b–f).
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transcriptional activity of the p21 promoter at all, which
eliminated the possibility that the inhibition by NSPc1 is an
artifact. Co-transfection of NSPc1 with c-Myc has a slight
synergistic transcriptional repression effect on the p21 pro-
moter ( 70% decrease, data not shown). Furthermore, we
found that NSPc1 inhibited p21 promoter-mediated luciferase
expression in a dose-dependent manner in COS-7 cells
(Figure 4c). Since COS-7 cells express abundant p53 proteins
while HeLa cells lack functional p53 (33), the same dose-
dependent assay was also performed in HeLa cells to see
whether the p53 protein is involved in the repression by
NSPc1 (Figure 4d). Results obtained from HeLa cells were
consistent with those from COS-7 cells, which indicated the
independence of p53 protein in NSPc1-mediated repression
in vivo.
p21 promoter repression by NSPc1 is dependent on the
RA response element (RARE element)
In order to ﬁnd out whether the NSPc1 protein is able to bind
the p21 promoter in vivo, we performed ChIP assay in HeLa
cells. A schematic map of the p21 promoter was drawn in
Figure 5a (31). As shown in Figure 5a and b, PCR product
representing the region ( 1357 to  1063) of p21 promoter
was immunoprecipitated with both RXRa antibody (Santa
Cruz) and NSPc1 antisera (13), while no band was visible
using pre-immunized sera or IgG. In contrast, no PCR prod-
ucts were visible when using the primers for the downstream
( 194 to +84) or the upstream ( 2264 to  1971) regions of
p21 promoter. Real time ChIP done in various HeLa cell
pools conﬁrmed the speciﬁc binding of NSPc1 on the p21
promoter region ( 1357 to  1063) (Figure 5c).
To ﬁnd out whether the effect of NSPc1 on p21 relies on
some important cis-elements in the proximal p21 promoter
(Figure 5a), such as the RARE element within the ( 1357
to  1063) region, several mutated constructs of the p21
promoter were used to detect the repression activity of
NSPc1. As shown in Figure 5d, in COS-7 cells, NSPc1 can
inhibit the activity of the 2.3 kb (wt, wild type), the 1.8 kb
(with the pivotal p53 binding site deleted) and the 2.3 kb
(with the proximal 1, 2 E-box mutated) fragments of the
p21 promoter, but not the RARE-mutated fragment. A similar
loss of function of NSPc1 on p21 RARE-mutated promoter
was also observed in HeLa cells (data not shown). All of
these results indicated that the RARE element within
the p21 promoter region ( 1357 to  1063) is crucial
for NSPc1-mediated repression of p21 promoter activity,
which also suggested that the RARE element is a potential
functional binding site of the NSPc1 protein.
RXRa deprives the repression effect of NSPc1 on the
p21 promoter through competing RARE element
RARE element is known as the binding site for RA receptors,
such as RXRa, b, g and RARa, b, g (34). To explore whether
any type of RA receptors can interfere with NSPc1 repression
on p21, we over-expressed RXRa with the reporter genes in
COS-7 cells and observed an induction of the basal level of
p21 promoter activity. When equal amounts of RXRa were
co-expressed with NSPc1, RXRa markedly overcame the
repression of NSPc1 (Figure 6a). Moreover, RXRa relieved
the repression of NSPc1 on the p21 promoter in a dose depen-
dent manner (Figure 6b, left). Increasing amounts of NSPc1
(maximum to 2-fold of RXRa) could not resume the repres-
sive effect on p21 once a certain amount of exogenous RXRa
existed (Figure 6b, right).
As RXRa is a native binding factor of RARE element, we
speculated that the over-expressed RXRa occupies the RARE
region and results in excluding NSPc1 from the p21
promoter. The following DNA pulldown assays sequentially
veriﬁed not only the binding ability of NSPc1 dependent on
the RARE element of p21 promoter, but the competitive
binding relationship between NSPc1 and RXRa as well.
A series of DNA pulldown assays were performed with
different biotinylated DNA probes representing the regions
( 1357 to  1063 and  194 to +84) of the p21 promoter
(Figure 5a). It is evident from the results that the probes of
region ( 1357 to  1063), but not of the region ( 194 to
Figure 3. NSPc1 specifically represses the expression of the CDK inhibitor
p21. (a) Semi-quantitative RT–PCR results (normalized by GAPDH level)
show the expression level of CDKIs in various HeLa stable cell pools. Bmi-1
was detected as a control of NSPc1-RNAi specificity. Similar results were
observed in three independent experiments. (b) Western blot results
confirmed that the expression levels of p21 protein in various stable cell
pools were reversely correlated with NSPc1 (normalized by b-actin protein
level).
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(Figure 6c). Here SP1-V5 and Bmi-1-V5 were included as
the positive and negative controls. However, NSPc1-V5 did
not bind the probes of region ( 1357 to  1063) any more
after RARE element was mutated, which suggested that
NSPc1 binding the region ( 1357 to  1063) of the p21 pro-
moter is dependent on RARE element. Furthermore, their
binding amounts on the RARE-contained region of the p21
promoter were positively correlated with the input amount
of COS-7 extracts, which contain over-expressed NSPc1-V5
or RXRa-V5, respectively (Figure 6d). This let us to the
hypothesis that RXRa can compete with NSPc1 for the
RARE element in vivo. So further in vivo DNA pulldown
assay used NSPc1-V5 over-expressed COS-7 extracts before
or after retinoic acid induction as the input samples
(Figure 6e). Up-regulated endogenous RA receptors including
RXRa competed for the RARE binding sites of the p21 pro-
moter probe ( 1357 to  1063) with over-expressed NSPc1-
V5. This result further conﬁrmed the competition between
NSPc1 and RXRa for the RARE element in vivo.
DISCUSSION
In the current study, we showed that NSPc1 increased the
fraction of S phase cells and promoted the G2/M phase
transition in HeLa and SH-SY5Y cells (Figure 1). These
effects were then conﬁrmed in stable HeLa cell pools
(Figure 2b and c). Detection on the expression of most of
CDKIs showed that the cell growth characteristics of the
HeLa stable cell pools were related to the alteration of
p21 expression both at the RNA and the protein levels
Figure 4. Transcriptional repression effect of NSPc1 on p21 promoter activity. (a) Repression activity assays of NSPc1. COS-7 cells were serially co-transfected
with equal amounts of the pcDNA6-FLAG, pcDNA6-FLAG-NSPc1 or pcDNA6-FLAG-Bmi-1 plasmid (300 ng/well) together with the reporter plasmid pGL3-
p21-2.3 kb-promoter construct (200 ng/well) and the internal control plasmid pRL-TK (100 ng/well). (b) Western blot results verified that each expression
construct was normally expressed in COS-7 cells. (c and d) Dosage-dependent transcriptional repression of p21-promoter by NSPc1. COS-7 or HeLa cells were
co-transfected with increased amounts of pcDNA6-FLAG-NSPc1 plasmid (100, 200, 300, 400, 500 ng/well) together with the reporter plasmid and pRL-TK
plasmid as above. Abbreviations: RLU, relative luciferase unit; CON, control (pcDNA6-FLAG-empty vector). Error bars, SDs. **P < 0.001 versus control.
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p21 negatively affects cell cycle progression (35–39),
the regulation of p21 would account for a possible molecular
mechanism through which NSPc1 controls tumor cell cycle
and cell proliferation. While the knockdown of NSPc1 is not
sufﬁcient to abrogate the colony formation ability of tumor
cells although it decreases cell growth (Figure 2d and g). So
further studies such as selective over-expression or knock-
out of NSPc1 in animal models are needed to prove the
pathogenetic role of NSPc1 in tumorigenesis.
p21 was originally characterized as an important effector in
p53-mediated cell cycle arrest (35–39). The expression of this
gene was mainly regulated in the transcription level (31).
Previous studies indicated that many transcription factors
other than p53 also can regulate p21 during cell differentia-
tion and growth arrest, such as c-Myc (32,40,41) and RA
receptors (34,42). Here we ﬁrstly demonstrated that NSPc1
represses p21 transcription as c-Myc does but Bmi-1 has no
effect on p21 transcription (Figure 4a and b). It agrees with
our previous view that the transcriptional repression process
Figure 5. NSPc1 binds directly to the p21 promoter via the RA response element. (a) Up: schematic depiction of the human p21 promoter illustrating regions
bound by some of the major regulatory factors, the arrow represents the transcription start site at +1; Down: table of the relative location of the three primer pairs
used in ChIP assays. (b) ChIP assays in ordinary HeLa cells. Three different regions of p21-promoter [as shown in (a)] were amplified after chromatin
immunoprecipitation from HeLa cell lysates using polyclonal anti-RXRa antibody (Santa Cruz), anti-NSPc1 antisera, pre-immune antisera or mouse IgG (as a
negative control). Primers to the second intron of GAPDH were used as the negative control. (c) Real-time ChIP in the ordinary HeLa cells and stable HeLa
pools. PCR primers were designed for amplification of the region ( 1357 to  1063). Amount of immunoprecipitated DNA was quantified by Absolute
Quantitative PCR. Error bars, SDs. (d) Repression activity assays of NSPc1 on the mutated p21 promoters. COS-7 cells were serially co-transfected with equal
amounts of the control plasmid pcDNA6-FLAG or pcDNA6-FLAG-NSPc1 (300 ng/well), the various pGL3-p21-promoter constructs (200 ng/well) as reporter
plasmid and the internal control plasmid pRL-TK (100 ng/well). Abbreviations: wt: wild type; mut, mutated; RARE, RA responsive element; RLU, relative
luciferase unit; CON, control (pcDNA6-FLAG-empty vector). Error bars, SDs. *P < 0.01 versus control.
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(13). We suppose here that NSPc1 is an important transcrip-
tional regulator of p21, whereas Bmi-1 is a key upstream
factor of the p16ARF/p19INK4a pathway (9,43). Moreover,
we showed the independence of p53 protein activity in
NSPc1-mediated repression of p21 in vivo (Figures 4d and
5d), and the NSPc1-mediated repression has a crosstalking
with the RA signaling pathway (Figures 5d and 6a, b).
Figure 6. The RARE element within the p21 promoter recruits both NSPc1 and RXRa. (a) Exogenous expression of RXRa deprives the repression effect of
NSPc1 on the p21 promoter. COS-7 cells were serially co-transfected with equal amounts of the pcDNA6-FLAG-empty, pcDNA6-FLAG-NSPc1 or/and
pcDNA6-FLAG- RXRa plasmid (300 ng/well) together with the reporter plasmid and pRL-TK plasmid. (b) Over-expression of NSPc1 could not resume the
repression effect of the p21-promoter once a certain amount of exogenous RXRa existed. COS-7 cells were co-transfected with the reporter plasmid, pRL-TK,
pcDNA6-FLAG-NSPc1 or pcDNA6-FLAG-RXRa together with increasing amounts of pcDNA6-FLAG-RXRa or pcDNA6-FLAG-NSPc1 as shown. Error bars,
SDs. Abbreviations: RLU, relative luciferase unit. (c) Binding ability of NSPc1-V5 and RXRa-V5 on the region ( 1357 to  1063) of the p21 promoter was
dependent on RARE element. Different biotinylated DNA probes (abbreviated as wt RARE, core promoter, and mut RARE, respectively) representing the
regions ( 1357 to  1063 and  194 to +84) of the p21 promoter were used to recruit the specific binding proteins when incubated with NSPc1-V5, RXRa-V5,
Bmi-1-V5 (negative control), or SP1-V5 (positive control) over-expressed COS7 extracts. Binding samples were detected by western blot with V5 monoclonal
antibody. Abbreviations: wt, wild type; mut, mutated. (d) Dose-dependent binding effect of NSPc1-V5 and RXRa-V5 on the region ( 1357 to  1063) of the p21
promoter. 0.25, 0.5, 0.75 and 1.0 mg of NSPc1-V5 and RXRa-V5 over-expressed COS7 extracts were used as the input. (e) Up-regulated endogenous RXRa
competed the RARE binding sites of the p21 promoter probe ( 1357 to  1063) with over-expressed NSPc1-V5. NSPc1-V5 over-expressed COS-7 extracts
before or after retinoic acid (10
 7M) induction for 3 days as the input samples.
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by forming multiprotein complexes at speciﬁc chromosomal
sites called polycomb response elements (PREs) (44,45),
but until now no exact ‘mammalian PRE’ consensus
sequence has been reported. It was difﬁcult for us to decide
exactly which promoter region of p21 should be used in the
ChIP experiments. However, recent studies showed that the
mammalian polycomb protein Bmi-1 can bind to a certain
site (around the transcription start site) in the proximal pro-
moter region of its target gene (46). So in the NSPc1-ChIP
assays, three representative promoter regions were selected
(Figure 5a and b). The selected proximal region ( 194 to
+84) of the p21 promoter represents the core promoter region,
which includes the TATA box, the SP1/SP3 binding sites, the
E-boxes and the transcription start site. We observed that the
repression of p21 by NSPc1 does not involve disturbing
the basal transcription machine, for there was no positive
signal from this core promoter region in the ChIP assay
(Figure 5b). The second selected distal region ( 2264 to
 1971), which dose not contain any typical binding site,
represents a random or non-speciﬁc region of the p21
promoter. The third selected region ( 1357 to  1063)
includes a typical RA response element, based on the reports
from Djabali’s lab that the polycomb group protein M33 is
able to control the accessibility of the RA response elements
in the vicinity of the Hox genes (47,48). In our ChIP assay,
a positive signal was obtained from the region ( 1357 to
 1063) (Figure 5b) and it was conﬁrmed by using real-
time ChIP in our stable HeLa cell pools (Figure 5c). This
indicated that a native NSPc1 protein complex is formed in
the vicinity of the RARE region in vivo. Further mutational
analysis of the p21 promoter revealed that the RARE
sequence, which is capable of forming a complex with RA
receptors, was critical for the repression function of NSPc1,
but neither the p53 binding site nor the p53 protein was
needed for the repression by NSPc1 (Figure 5d). Thus, a rela-
tionship between the polycomb group protein NSPc1 and the
RA signaling pathway was revealed: the RXRa antagonizes
the repression of NSPc1 on the p21 promoter, while NSPc1
does not affect exogenous RXRa targeting of RARE element
(Figure 6a and b). Furthermore, DNA pulldown assays
sequentially veriﬁed the binding ability of NSPc1 dependent
on the RARE element of the p21 promoter and a competitive
binding relationship between NSPc1 and RXRa both in vitro
(Figure 6c and d) and in vivo (Figure 6e). These outcomes
raise some interesting issues with respect to the roles of
both polycomb members and the RA regulatory mechanisms.
We propose that once the excessive RAR/RXR(s) dimer (s)
occupy the RA response element in the p21 promoter,
NSPc1 can no longer target and repress p21 as usual. Thus
the RARE region may serve as a switch of p21 expression,
which is controlled by the balance of polycomb repressions
and the RA signaling pathways.
However, there are still some pivotal questions to be
answered: for example, whether NSPc1 can directly bind to
the RARE region? Although Mel-18 (a mammalian
Psc homologue) has been demonstrated to bind DNA
in vitro (11), most polycomb proteins cannot bind to DNA
directly. In vitro EMSA assay showed that recombinant
NSPc1 protein alone could not bind to the RARE region of
the p21 promoter (data not shown), which indicated other fac-
tors are needed for targeting. So which protein recruits NSPc1
to the RARE region in the p21 promoter remains an intri-
guing and unresolved question. We speculate that some
unknown co-binding factors (CoB) may form complexes
with NSPc1 in vivo and facilitate NSPc1 to recognize and tar-
get the RARE element (Figure 7a and b). It could be very
interesting to identify the NSPc1 involved protein complex
that binds the RARE element.
Taken together, current data support the hypothesis that
NSPc1 has a positive role in promoting tumor cell cycle tran-
sition and cell proliferation, at least partially through down
regulating the CDK inhibitor p21 via the RARE element.
Furthermore, our results not only give a possible working
model for the ‘mammalian PREs’, but connect transcriptional
repression by mammalian PcGs with p21 and the RA
signaling pathways as well (Figure 7c).
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